By merging clinical expertise with a telehealth-first approach, we help you navigate the complexities of GLP-1 therapy with transparency and ease
With March being National Nutrition Month , now is as good a time as any for a reminder about how important nutrition and positive lifestyle changes can be in your lifeeven when you have uterine fibroids
How Copper Peptide Works: Signaled Repair GHK-Cu takes the opposite approach
Patrick Kee, MD, PhD, a cardiologist at Vital Heart & Vein, who was not involved in the study, noted the following about the studys results: The investigators demonstrated that the therapeutic efficacy of semaglutide on the primary cardiovascular composite endpoint indeed emerged early and persisted over the initial three months (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.41-0.95) and the subsequent six months (HR 0.60, 95% CI 0.44-0.81). While the underlying mechanisms of semaglutides early clinical benefits remain under investigation, these findings suggest an encouraging intervention capable of altering the trajectory of [patients with obesity] with established cardiovascular disease but without a diagnosis of diabetes, he told Medical News Today
1 The results were clear: Semaglutide group: 15.8% average weight loss Liraglutide group: 6.4% average weight loss 70.9% of semaglutide participants lost at least 10% of body weight, compared with 25.6% on liraglutide 55.0% of semaglutide participants lost at least 15%, compared with 12.0% on liraglutide This trial provides the strongest available evidence that Wegovy is substantially more effective than Saxenda for weight loss
2024;8:e304
